Maja Matic1,2, Joost Lm Jongen3, Laure Elens4,5, Saskia N de Wildt2,6, Dick Tibboel2, Peter Ae Sillevis Smitt3, Ron Hn van Schaik1. 1. Department of Clinical Chemistry, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands. 2. Department of Pediatric Surgery, Erasmus MC - University Medical Center Rotterdam, Sophia Children's Hospital, Rotterdam, The Netherlands. 3. Department of Neurology, Erasmus MC - University Medical Center Rotterdam, Rotterdam, The Netherlands. 4. Louvain Drug Research Institute, Université catholique de Louvain, Brussels, Belgium. 5. Louvain Centre for Toxicology & Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et clinique (IREC), Université catholique de Louvain, Brussels, Belgium. 6. Department of Pharmacology & Toxicology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
Abstract
AIM: To assess association between genetic variants and opioid requirement in cancer patients. MATERIALS & METHODS: A prospective observational trial of 243 advanced cancer patients with inadequate analgesia treated by the palliative care team was analyzed for ABCB1, ARRB2, COMT, GCH1, IL1RN, KCNJ6, OPRM1, RHBDF2, SCN9A and Stat6 polymorphisms. RESULTS: For patients carrying OPRM1 118AG/GG and COMT 472GG (Val158Val) or these genotypes alone, a significant higher median percentage dose increase was observed (95.2% [32.8-345]) compared with OPRM1 118AA and COMT 472GA/AA (158Met allele carriers; 48.5% [0-98.8]; p = 0.0016). No associations were found with morphine equivalent dose after consultation palliative care team or ketamine use. CONCLUSION: Patients with the combined OPRM1 118AG/GG and COMT 472GG genotype required 50% higher dose increase for sufficient analgesia.
AIM: To assess association between genetic variants and opioid requirement in cancerpatients. MATERIALS & METHODS: A prospective observational trial of 243 advanced cancerpatients with inadequate analgesia treated by the palliative care team was analyzed for ABCB1, ARRB2, COMT, GCH1, IL1RN, KCNJ6, OPRM1, RHBDF2, SCN9A and Stat6 polymorphisms. RESULTS: For patients carrying OPRM1 118AG/GG and COMT 472GG (Val158Val) or these genotypes alone, a significant higher median percentage dose increase was observed (95.2% [32.8-345]) compared with OPRM1 118AA and COMT 472GA/AA (158Met allele carriers; 48.5% [0-98.8]; p = 0.0016). No associations were found with morphine equivalent dose after consultation palliative care team or ketamine use. CONCLUSION:Patients with the combined OPRM1 118AG/GG and COMT 472GG genotype required 50% higher dose increase for sufficient analgesia.
Authors: Elyse M Cornett; Michelle A Carroll Turpin; Allison Pinner; Pankaj Thakur; Tamizh Selvan Gnana Sekaran; Harish Siddaiah; Jasmine Rivas; Anna Yates; G Jason Huang; Anitha Senthil; Narjeet Khurmi; Jenna L Miller; Cain W Stark; Richard D Urman; Alan David Kaye Journal: Curr Oncol Rep Date: 2020-02-06 Impact factor: 5.075